Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis - Wikidata - awgldk - TriplyDB

Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis

Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis

http://www.wikidata.org/entity/Q35030586

about

Lipid-lowering efficacy of atorvastatin HMG CoA reductase inhibitors (statins) for dialysis patients Kidney Transplantation in the Diabetic Patient Pharmacologic management of chronic reno-cardiac syndrome Lipid abnormalities in kidney disease and management strategies Dietary Interventions for Type 2 Diabetes: How Millet Comes to Help Rosuvastatin calcium in acute coronary syndromes.HDL cholesterol, apolipoproteins, and cardiovascular risk in hemodialysis patients.Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis.The effects of different doses of atorvastatin on serum lipid profile, glycemic control, and liver enzymes in patients with ischemic cerebrovascular accident.Survival Benefit of Statins in Hemodialysis Patients Awaiting Renal Transplantation Meta-analysis of statin therapy in maintenance dialysis patients.A meta-analysis of the effects of statin treatment on cardiovascular events and all-cause mortality in diabetic dialysis patients Effects of statins on cardiorenal syndrome.What's the Optimal Lipids Level for Dialysis Patients? A Cohort Study from a Chinese Dialysis Center in a University Hospital.Statins for renal patients: a fiddler on the roof?Diagnosis and treatment of coronary artery disease in hemodialysis patients evaluated for transplant Contemporary Management of Coronary Artery Disease and Acute Coronary Syndrome in Patients with Chronic Kidney Disease and End-Stage Renal Disease.Dyslipidemia in patients with chronic and end-stage kidney disease.Statins in the management of dyslipidemia associated with chronic kidney disease.Is lipid management effective for all stages of CKD?.Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations.Statin wars: the heavyweight match--atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease.Serum lipids and prevention of atherosclerotic cardiovascular events in hemodialysis patients.Results of the 4D study: ten years of follow-up?Safety and efficacy of statins in patients with end-stage renal disease.Dyslipidemia in Dialysis Patients.Does pharmacotherapy improve cardiovascular outcomes in hemodialysis patients?HDL abnormalities in nephrotic syndrome and chronic kidney disease.Lipid lowering in renal disease.Pharmacokinetic and pharmacodynamic profile of rosuvastatin in patients with end-stage renal disease on chronic haemodialysis.Pharmacologic treatment in dialysis patients hospitalized for cardiovascular reasons: do we follow the guidelines?Regional evidence and international recommendations to guide lipid management in Asian patients with type 2 diabetes with special reference to renal dysfunction.Still a reasonable goal: Targeting cholesterol in dialysis and advanced chronic kidney disease patients.Anti-atherosclerotic activity of root bark of Premna integrifolia Linn. in high fat diet induced atherosclerosis model rats.Japanese Society for Dialysis Therapy guidelines for management of cardiovascular diseases in patients on chronic hemodialysis.High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease.Predictors of atherosclerotic events in patients on haemodialysis: post hoc analyses from the AURORA study.Determinants of coronary artery calcification in maintenance hemodialysis patients.Beneficial effect of statins in patients receiving chronic hemodialysis following percutaneous coronary intervention: A nationwide retrospective cohort study.

P2860

Q24187301-24CBF196-B013-44B1-8DB5-43FAF98EF169 Q24198108-0579CDE5-231C-4DBD-8030-A978E825EE91 Q26799452-0A2D7E5C-DC36-4707-BB35-C41832853AF2 Q26829812-322A1C83-DE46-4859-8C63-7198E6EECD6E Q27024982-CD17ADD4-ADF1-4271-8B70-E844052717DE Q28079718-BDA9A4B8-AFD0-4F06-ABEA-4132A5E8D976 Q34338367-32595BD0-27D8-401D-927B-E9AC9A683F08 Q35027220-5A8E50B8-17F9-4C8B-AF6C-AB1B0BA73C68 Q35051225-EAC656E5-6E61-4AA7-81EF-A489EE9691F3 Q35160603-A4D7B3B2-C7BE-40AC-B7CB-70DD02DEF989 Q35675305-D8CB3F63-3BE3-438F-BD08-84F7F20DD24E Q35682013-7DCD38EB-0016-4B69-8B2F-D797C7EF39C4 Q35756365-83F27242-F7EE-476A-B825-EB7C8991879F Q36077149-2E195CB6-56C2-452E-9D37-088829D47FF8 Q36228385-CEFDBD04-E133-48E2-8FBC-7DB6E80B849E Q36361057-C6255CC9-A22A-4858-BE63-B6FE2FF760BB Q36555462-AC046A50-3509-40F3-9819-B3F701390DC6 Q36721107-F0B934BC-EC34-4A48-AF48-9DC08F96926D Q37447007-743773C7-4C06-4C0E-A4CB-57243CC9531F Q37986355-862C40BD-3D80-4952-9802-BC084CC4AB98 Q38076216-6C940DF4-A1F6-4EC2-8378-13C414289053 Q38076217-3D96543A-AC98-4333-8B37-EA583F887C86 Q38079913-B24C0250-0825-420D-9793-07A0E0A723DE Q38144931-F9506218-3C6F-486C-B3AC-648B12C45D21 Q38156020-EA59666A-7180-4800-AC57-9226311E2149 Q38164683-9CE32BFA-5A86-40D8-97F2-42B33EB1DA85 Q38412228-D0CEDCCE-0551-4345-B4EA-D2940FA9822B Q38602442-CCC52844-4958-4FE8-9E38-483B8FD65D02 Q38633497-15FAE8D9-1757-43B9-98DD-7A0B37AD675D Q41690923-BA76DE3F-D22C-483C-9B73-0C6B6BE8AD76 Q42692011-4B7CB921-044A-411B-ACAC-AB5CCC641267 Q45784975-CE0980DB-6D4C-4274-AA55-9B2F6307E0D2 Q47900774-51C782F1-6B5E-4817-B8DA-BB21E61EBA91 Q48038746-CA12B192-684B-4D94-AA33-7CD1915EC8DB Q49191105-ADD80C18-1251-4954-8DAE-378057754949 Q50502242-3BC04063-5894-4E05-8A23-2C47F0DE0B9C Q51052574-4906B2EF-8A0C-4C2B-9DA1-0B48A054EA0E Q51353168-334C57BF-DD3D-44A4-8236-8A83BF8D795C Q53019639-52CBD07F-8593-4A85-A17F-98117446509C Q55512228-DA8F7194-8A4D-4E48-AF5A-19A340D84B27

P2860

Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis

http://www.wikidata.org/entity/Q35030586

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Atorvastatin and low-density l ...... litus patients on hemodialysis

@ast

Atorvastatin and low-density l ...... litus patients on hemodialysis

@en

type

label

Atorvastatin and low-density l ...... litus patients on hemodialysis

@ast

Atorvastatin and low-density l ...... litus patients on hemodialysis

@en

prefLabel

Atorvastatin and low-density l ...... litus patients on hemodialysis

@ast

Atorvastatin and low-density l ...... litus patients on hemodialysis

@en

P1433

Q35030586-5691C6B1-EBFB-4202-AF7A-A8F43D149E60

P1476

Q35030586-8C688FA8-F1DE-4148-89EE-A36E097B5AA4

P2093

Q35030586-3A7B6070-0487-49E0-8D8F-787D94408D09

Q35030586-425E194C-2BE2-4D0C-A2A6-65CA42C8378D

Q35030586-44020F41-7FDE-4393-98AD-EDCB13F3AA74

Q35030586-53C91605-D04B-4EC9-8E6C-2A3315991B11

Q35030586-5DA60FB5-FC66-4E7F-B92C-A7F4DE8B3D15

Q35030586-60DDD0F1-A8DB-48C0-8BFA-1933EF74F448

Q35030586-8D67BDF2-0360-48EE-AA56-F89AA8AE28C3

Q35030586-BFE5E249-D970-44E5-9A46-F8F622C53624

Q35030586-CDD8ADBE-E1E7-49BA-A7AD-5708C0E34CEB

Q35030586-D1010F60-57CC-42A0-8BE5-C67E65EA339B

P2860

Q35030586-00046B89-4920-4085-B925-980420D1B822

Q35030586-08B7E435-1A44-4856-A208-0248E30E02FB

Q35030586-09604178-5E64-42EC-A150-871C227BDB9A

Q35030586-096D5D0C-88B8-48B8-84C7-8631CC01F74D

Q35030586-0AC6B13A-85AB-4F66-B31D-4842E827F326

Q35030586-1A765309-3620-4250-B97A-62880C4A8834

Q35030586-21A5690E-C76A-4658-B858-49B00EF15095

Q35030586-2968F542-EA29-4F1D-8F83-DD8278F5A382

Q35030586-2B74FE5D-60C9-4F1B-A7BC-039C30590B9E

Q35030586-2CC22A5E-BBB9-43F3-9C0B-C4DCD63A8C29

P304

Q35030586-36C64A48-3D01-4E38-81E9-1A0C9091A0C1

P31

Q35030586-C9D72087-D5B7-49A8-BF31-7548E89CE02E

P356

Q35030586-2D11815A-3F7B-4B90-856C-62A13859DA8B

P433

Q35030586-1F94EBD7-62E8-4467-892C-EFC8018E121F

P478

Q35030586-E0EFD71E-F5FA-4CC4-831A-6B4910A3ADF3

P50

Q35030586-4A69E0E3-C8FB-468A-95CD-8D0354B93E73

Q35030586-65A20BD3-B90C-4C7D-A01B-5A03120FC8EF

Q35030586-CF609C42-1819-4FB9-BE0E-991EF007E588

P577

Q35030586-6A5A4CCF-2662-4C7D-8F5D-455CFBC5FBED

P698

Q35030586-010DA3CF-77ED-40B1-BC28-7D81FC510C10

P921

Q35030586-5E7E6160-7E37-43C4-A1CB-B404CDA356CF

Q35030586-D77E5D89-09BA-4FDF-B6FC-B5D144A0A285

P932

Q35030586-A33E22D6-3703-4C0D-AAF9-BB248B9A757C

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Atorvastatin and low-density l ...... litus patients on hemodialysis

@en

P2093

Bernd Genser

http://www.w3.org/2001/XMLSchema#string

Christiane Drechsler

http://www.w3.org/2001/XMLSchema#string

Christoph Wanner

http://www.w3.org/2001/XMLSchema#string

Eberhard Ritz

http://www.w3.org/2001/XMLSchema#string

German Diabetes and Dialysis Study Investigators

http://www.w3.org/2001/XMLSchema#string

Hallvard Holdaas

http://www.w3.org/2001/XMLSchema#string

Ingar Holme

http://www.w3.org/2001/XMLSchema#string

Karl Winkler

http://www.w3.org/2001/XMLSchema#string

Tatjana Stojakovic

http://www.w3.org/2001/XMLSchema#string

Vera Krane

http://www.w3.org/2001/XMLSchema#string

P2860

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths.

Survival analysis for recurrent event data: an application to childhood infectious diseases.

The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis.

P304

1316-1325

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.09121010

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Hubert Scharnagl

Tanja B Grammer

P577

2011-04-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21493741

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

LDL cholesterol

P932

3109927

http://www.w3.org/2001/XMLSchema#string